LY6 Gene Expression Detection for IBD Diagnosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for additional biological markers for the diagnosis of inflammatory bowel disease (IBD), as existing methods are insufficient for accurately detecting and differentiating between ulcerative colitis (UC) and Crohn's Disease (CD).

Innovation Solution

The method involves detecting increased expression of LY6H, LYPD1, LYPD3, and LYPD5 genes in gastrointestinal tissue samples using detectable agents that interact with their proteins or nucleic acids, comparing the expression levels to control samples to diagnose IBD, UC, or CD.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If existing diagnostic methods are used for IBD, then diagnosis can be performed, but accuracy in differentiating between UC and CD is insufficient

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidability to differentiate disease types

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent segments the diagnostic approach by identifying and measuring expression levels of specific gene families (LY6H, LYPD1, LYPD3, LYPD5) rather than using general diagnostic methods. This segmentation allows differentiation between UC and CD by detecting specific gene expression patterns unique to each disease type, thereby improving both diagnostic accuracy and the ability to distinguish between disease subtypes.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies parameter changes by measuring gene expression levels (a molecular parameter) rather than relying on traditional clinical parameters. By monitoring the expression levels of specific LY6 family genes, the patent transforms the diagnostic process into a quantitative measurement that can accurately differentiate between UC and CD based on distinct gene expression profiles.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If additional biological markers are sought, then diagnostic accuracy improves, but complexity of detection methods increases

Engineering Contradiction:

Improvediagnostic accuracyVSAvoiddetection method complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent applies universality by developing a detection method that can simultaneously identify multiple disease states (IBD, UC, and CD) using a single panel of gene markers. The same detection system measures expression levels of LY6H, LYPD1, LYPD3, and LYPD5 genes to diagnose different conditions, eliminating the need for separate diagnostic procedures for each disease type and reducing overall system complexity.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent merges the detection of multiple gene family members into a single diagnostic approach. By combining the measurement of LY6H, LYPD1, LYPD3, and LYPD5 expression levels in one assay, the patent achieves comprehensive diagnostic capability while simplifying the detection process compared to using separate methods for each marker.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentEP2140021B1Methods for detecting inflammatory bowel disease

Publication Date: 2012.01.11 GENENTECH INC

Figure 1A
Figure 1B
Figure 2A

AI summary

The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting increased expression of LY6 genes in the tissues or cells of the mammal relative to a control.